Bacterial topoisomerase I inhibitors – IP 1517

Microbial pathogens are becoming increasingly resistant tocurrent antibiotics, limiting the availability of clinical treatment optionsfor bacterial infections. It is imperative to develop novel classes ofantibacterial compounds, preferably against a new target, to avoidcross-resistance. Clinically, topoisomerase enzymes represent attractive andsuccessful targets for anticancer and antibacterial chemotherapy. Bacterialtopoisomerase I is a novel topoisomerase target that is essential for theviability of pathogens including mycobacteria, Helicobacter pylori andPseudomonas aeruginosa. Researchers at FIU and the University of Hawai‘i havesynthesized fluoroquinophenoxazine analogs and demonstrated their activities astopoisomerase I inhibitors and bactericidal antibacterial agents. Anne Laure Schmitt Olivier 305-348-5948

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More